DCF Advisers’s Altimmune ALT Stock Holding History

DCF Advisers’s Portfolio ALT Stock Details ALT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$45.3K	Sell	14,700 -4,000	-21%	-$17K	0.01%	86
2025 Q4	$67.5K	Buy	+18,700	New	+$81.5K	0.02%	94
2025 Q3	–	Sell	-10,770	Closed	-$41.7K	–	97
2025 Q2	$41.7K	Sell	10,770 -11,000	-51%	-$59.5K	0.02%	82
2025 Q1	$109K	Buy	+21,770	New	+$138K	0.05%	80
2024 Q4	–	Sell	-37,868	Closed	-$233K	–	90
2024 Q3	$233K	Sell	37,868 -5,000	-12%	-$33.9K	0.09%	84
2024 Q2	$285K	Sell	42,868 -53,357	-55%	-$394K	0.15%	78
2024 Q1	$980K	Sell	96,225 -19,000	-16%	-$193K	0.48%	46
2023 Q4	$1.3M	Sell	115,225 -4,750	-4%	-$19.8K	0.7%	34
2023 Q3	$312K	Hold	119,975	–	–	0.17%	72
2023 Q2	$424K	Buy	119,975 +43,000	+56%	+$193K	0.22%	65
2023 Q1	$325K	Sell	76,975 -3,705	-5%	-$44K	0.2%	56
2022 Q4	$1.33M	Sell	80,680 -148,320	-65%	-$1.67M	0.9%	29
2022 Q3	$2.92M	Sell	229,000 -106,180	-32%	-$1.57M	1.89%	19
2022 Q2	$3.92M	Buy	335,180 +19,180	+6%	+$118K	2.34%	13
2022 Q1	$1.92M	Buy	316,000 +35,300	+13%	+$260K	0.84%	35
2021 Q4	$2.57M	Buy	280,700 +41,500	+17%	+$441K	1.04%	28
2021 Q3	$2.71M	Buy	239,200 +93,450	+64%	+$1.14M	1.19%	24
2021 Q2	$1.44M	Buy	+145,750	New	+$1.99M	0.51%	42

Other funds holding ALT

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

DCF Advisers's ALT Position: Q1 2026 in Review

DCF Advisers reduced its Altimmune (ALT) stake by 21% in Q1 2026, selling an estimated $17K and leaving 14,700 shares worth $45.3K. The position accounts for 0.01% of the portfolio, ranked #86.

DCF Advisers first reported a position in ALT in Q2 2021 and has held it in 18 quarters since. The position peaked at $3.92M in Q2 2022. 173 funds tracked by Wall St. Rank hold ALT as of Q1 2026.

DCF Advisers held 14,700 shares of Altimmune worth $45.3K as of Q1 2026.
DCF Advisers sold 4,000 Altimmune shares in Q1 2026, an estimated $17K.
Altimmune made up 0.01% of DCF Advisers's portfolio in Q1 2026, its #86 holding.
DCF Advisers first reported a position in Altimmune in Q2 2021 and has held it in 18 quarters since.
DCF Advisers's Altimmune position peaked at $3.92M in Q2 2022.
173 funds tracked by Wall St. Rank held Altimmune as of Q1 2026.

Based on DCF Advisers's 13F filing for Q1 2026, filed 11 May 2026.